Associated tags: Infection, Pharmaceutical industry, Armata, NYSE, Staphylococcus aureus, Pseudomonas aeruginosa, Conference, GMP, DEL, Therapy, MSD, Drug development, Merck
Locations: CALIFORNIA
LOS ANGELES, Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that topline data from the Company's Phase 1b/2a SWARM-P.a.
Key Points:
- LOS ANGELES, Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that topline data from the Company's Phase 1b/2a SWARM-P.a.
- clinical trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) will be mentioned during the North American Cystic Fibrosis Conference (NACFC) Plenary II session.
- The conference is being held November 2-4, 2023, at the Phoenix Convention Center in Phoenix, AZ.
- Armata announced positive topline data from the SWARM-P.a.
Retrieved on:
Thursday, October 19, 2023
LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its Chief Medical Officer, Mina Pastagia, M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25th.
Key Points:
- LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its Chief Medical Officer, Mina Pastagia, M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25th.
Retrieved on:
Thursday, September 21, 2023
MARINA DEL REY, Calif., Sept. 21, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a panel discussion at the Cantor Global Healthcare Conference, which is being held in New York from September 26-28, 2023.
Key Points:
- MARINA DEL REY, Calif., Sept. 21, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a panel discussion at the Cantor Global Healthcare Conference, which is being held in New York from September 26-28, 2023.
- Armata's panel discussion is scheduled for Tuesday, September 26, from 2:45-3:15 PM ET.
HIV/AIDS,
Bangladesh Technical Education Board,
Staphylococcus aureus,
Patient,
PEPFAR,
Infection,
Walter Reed Army Institute of Research,
Walter Reed Army Medical Center,
Therapy,
Internal medicine,
CDC,
Pseudomonas aeruginosa,
CGMP,
Allergy,
Health,
Pennsylvania State University,
Milton Hershey School,
Staphylococcus,
AIDS,
United States Department of the Army,
Combat,
President's Emergency Plan for AIDS Relief,
Management,
Pharmaceutical industry,
Armata MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"). The gross proceeds of the credit agreement at closing are $25 million before transaction‐related expenses. Armata also announced today a leadership transition whereby Dr. Deborah L. Birx will succeed Dr. Brian Varnum as the Chief Executive Officer of the Company, effective immediately. Dr. Birx will also join Armata's Board of Directors.
Key Points:
- Armata also announced today a leadership transition whereby Dr. Deborah L. Birx will succeed Dr. Brian Varnum as the Chief Executive Officer of the Company, effective immediately.
- Proceeds from the $25 million new financing transaction will be used to advance the Company's pipeline of therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.
- "I would also like to thank Brian for his many years of service to Armata, dating back to 2012.
- I am excited about the recent advances and see multiple opportunities to accelerate the Company's progress and drive value creation.
Retrieved on:
Monday, November 28, 2022
MSD,
Staphylococcus aureus,
Drug development,
GMP,
Merck,
Infection,
Armata,
Pseudomonas aeruginosa,
NYSE,
DEL,
Conference,
Pharmaceutical industry MARINA DEL REY, Calif., Nov.28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the company will participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage, which is being held virtually on November 30, 2022.
Key Points:
- MARINA DEL REY, Calif., Nov.28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the company will participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage, which is being held virtually on November 30, 2022.
- Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.
- Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
- Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Retrieved on:
Thursday, February 17, 2022
MSD,
Armata,
Staphylococcus aureus,
Metagenomics,
Pseudomonas aeruginosa,
Drug development,
Merck,
GMP,
Infection,
Therapy,
Antibiotics,
Vaccine To register for the Chardan event, please use the following link: Chardan Metagenomics and Microbiome Medicines Summit
Key Points:
- To register for the Chardan event, please use the following link: Chardan Metagenomics and Microbiome Medicines Summit
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.
- Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
- In addition, in collaboration with Merck, known as MSD outside ofthe United StatesandCanada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
- Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Retrieved on:
Thursday, November 4, 2021
MSD,
Medication,
DEL,
Time,
Armata,
Drug development,
Merck,
NYSE,
Staphylococcus aureus,
GMP,
Phage therapy,
Congress,
Pseudomonas aeruginosa,
Infection,
Drug,
Urinary tract infection,
Therapy,
Pharmaceutical industry In its seventh year, the Congress will attract more than 400 attendees from around the world and features more than 150 speakers.
Key Points:
- In its seventh year, the Congress will attract more than 400 attendees from around the world and features more than 150 speakers.
- It is the world's largest and most commercially focused gathering of antimicrobial resistance stakeholders globally.
- Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
- Armata is committed to advancing its bacteriophage-based technology with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Retrieved on:
Tuesday, November 2, 2021
MSD,
Medication,
DEL,
Drug development,
Merck,
AP,
NYSE,
Staphylococcus aureus,
GMP,
Phage therapy,
SEC,
Communication,
Pseudomonas aeruginosa,
Annual report,
Forward-looking statement,
Risk,
Company,
Clinical trial,
Infection,
COVID-19,
Therapy,
Bacteriophage,
Pharmaceutical industry "Armata's innovative phage therapy pipeline will be enhanced by our commitment to build out a new R&D facility that offers expanded GMP manufacturing capacity to support future pivotal studies and commercial launch," stated Dr. Brian Varnum, Chief Executive Officer of Armata.
Key Points:
- "Armata's innovative phage therapy pipeline will be enhanced by our commitment to build out a new R&D facility that offers expanded GMP manufacturing capacity to support future pivotal studies and commercial launch," stated Dr. Brian Varnum, Chief Executive Officer of Armata.
- "In addition, we believe this new, state-of-the-art facility is essential for our novel product form given the scarcity of phage-specific manufacturing capacity.
- Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
- Armata is committed to advancing its bacteriophage-based technology with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Retrieved on:
Wednesday, September 8, 2021
MARINA DEL REY, Calif., Sept. 8, 2021 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
Key Points:
- MARINA DEL REY, Calif., Sept. 8, 2021 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
- The presentation will be available on-demand starting at 7:00 AM ET on September 13, 2021.
- If you are an institutional or retail investor, and would like to listen to the Company's presentation, click HERE for the conference.
- Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
MARINA DEL REY, Calif., Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its current Chief Executive Officer, Todd R. Patrick, is retiring from day-to-day active management of the Company, effective today. The Company's current President and Chief Development Officer, Brian Varnum, Ph.D., has been appointed Chief Executive Officer. Mr. Patrick will continue to serve on Armata's Board of Directors and has agreed to act as a special advisor to the Company through at least 2022.
Key Points:
- MARINA DEL REY, Calif., Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its current Chief Executive Officer, Todd R. Patrick, is retiring from day-to-day active management of the Company, effective today.
- The Company's current President and Chief Development Officer, Brian Varnum, Ph.D., has been appointed Chief Executive Officer.
- "At the same time, we are fortunate to have someone with Brian's extensive drug development experience on the team and I would like to congratulate him on his well-deserved elevation to the Chief Executive Officer role."
- Armata is committed to advancing its bacteriophage-based technology with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
